deng yue
deng yue

deng yue

      |      

Prenumeranter

From traditional ARi to Rezvilutamid: A breakthrough in the "blood-brain barrier" of endocrine therapy for prostate cancer.

From traditional ARi to Rezvilutamid: A breakthrough in the "blood-brain barrier" of endocrine therapy for prostate cancer.
deng yue
5 Visningar · 22/01/26

Rezvilutamide reduces blood-brain barrier permeability and central nervous system toxicity through innovative molecular structure. It is used to treat patients with metastatic hormone-sensit..